Core Insights - Yantai's biopharmaceutical industry has reached a scale of 212 regulated enterprises, with a cumulative launch of 6 class 1 new drugs in recent years, indicating significant growth in the sector [1][3][4] Group 1: Industry Development - The "Blue Pharmaceutical Valley" in Yantai has become a core area for the biopharmaceutical industry, with a total investment of 12 billion yuan and a construction area of 1.3 million square meters, attracting 34 biopharmaceutical companies [2][3] - Yantai's biopharmaceutical industry has achieved over 100 billion yuan in annual revenue for several consecutive years, establishing itself as a key player in China's biopharmaceutical landscape [3][4] - The city has implemented a "chain leader system" to enhance the biopharmaceutical industry, focusing on extending the industrial chain, improving the value chain, and integrating the supply chain [3][4] Group 2: Innovation and Infrastructure - Yantai has established a comprehensive vertical ecosystem for the biopharmaceutical industry, covering product research and development, results transformation, inspection and approval, and production and sales [4][5] - The city has launched 6 class 1 new drugs in recent years, leading the province, and aims to average 1-2 new class 1 drugs annually over the next five years [4][5] - The "Blue Pharmaceutical Valley" has the largest area in China for nuclear medicine production environmental assessment qualifications, with 12 class 1 nuclear drugs currently in clinical trials [5][6] Group 3: Strategic Focus Areas - Yantai is focusing on two key areas: medical isotopes and radioactive drugs, as well as cell and gene therapy, while also nurturing growth in innovative drugs, high-end generics, high-end medical devices, and traditional Chinese medicine [5][6] - The city has invested 297 million yuan to establish a top-tier cell product pilot platform, significantly reducing the landing costs for enterprises and attracting more cell drug companies [5][6]

Core Viewpoint - Dongcheng Pharmaceutical has received approval from the National Medical Products Administration for a new specification of its heparin sodium injection, indicating a positive development for the company's product portfolio [1] Group 1 - Dongcheng Pharmaceutical's wholly-owned subsidiary, Yantai Dongcheng Northern Pharmaceutical Co., Ltd., has been notified of the approval for the new specification (0.2ml: 5000AXaIU) of heparin sodium injection [1]

Group 1 - The core point of the article is that Dongcheng Pharmaceutical has received approval for a new specification of its low molecular weight heparin product, dalteparin sodium injection, from the National Medical Products Administration [1] - The newly approved specification is 0.2ml: 5000AXaIU, which expands the product's market offerings [1] - Dalteparin sodium injection is primarily used for the treatment of acute deep vein thrombosis, highlighting its significance in the therapeutic area of anticoagulation [1]

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its wholly-owned subsidiary, Yantai Dongcheng Northern Pharmaceutical Co., Ltd., received a notification from the National Medical Products Administration regarding the approval of a new specification (0.2ml: 5000AXaIU) for its low molecular weight heparin product, Daltaparin Sodium Injection [1] Group 1 - The newly approved specification for Daltaparin Sodium Injection is aimed at enhancing the product's market offerings [1] - Daltaparin Sodium Injection is primarily used for the treatment of acute deep vein thrombosis and for preventing thrombus formation during hemodialysis and blood filtration in patients with acute or chronic renal failure [1] - The product also addresses unstable coronary artery diseases, including unstable angina and non-Q wave myocardial infarction, as well as preventing surgery-related thrombus formation [1]

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its wholly-owned subsidiary, Yantai Dongcheng Northern Pharmaceutical Co., Ltd., received a notification from the National Medical Products Administration regarding the approval of a new specification (0.2ml: 5000AXaIU) for its low molecular heparin product, Dalteparin Sodium Injection [1] Group 1: Product Information - Dalteparin Sodium Injection is a low molecular weight heparin preparation with anticoagulant properties, primarily indicated for the treatment of acute deep vein thrombosis [1] - The product is also used to prevent acute renal failure or chronic renal insufficiency during hemodialysis and blood filtration, as well as to treat unstable coronary artery diseases such as unstable angina and non-Q wave myocardial infarction [1] - Additionally, it is indicated for the prevention of thromboembolism associated with surgical procedures [1]

东诚北方于2025年1月向国家药品监督管理局药品审评中心（CDE）递交了达 肝素钠注射液（0.2ml：5000AXaIU）增加规格补充申请，并于2025年1月26日获 得受理。2025年12月收到《药品补充申请批准通知书》，审评结论为：经审查， 本品此次申请事项符合药品注册的有关要求，同意本品如下补充申请事项：增加 0.2ml：5000AXaIU规格，核发药品批准文号。 证券代码：002675 证券简称：东诚药业 公告编号：2025-072 烟台东诚药业集团股份有限公司 关于全资子公司药品达肝素钠注射液增加规格获批上市的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 近日，烟台东诚药业集团股份有限公司（以下简称"公司"）收到全资子公 司烟台东诚北方制药有限公司（以下简称"东诚北方"）的通知，通知其收到国 家药品监督管理局下发的《药品补充申请批准通知书》，达肝素钠注射液新增规 格（0.2ml：5000AXaIU）获批上市。相关信息如下： 2.其他相关信息 药品名称 达肝素钠注射液 剂型 注射剂 申请事项 申请在已获批上市的达肝素钠注射液，规格：0.3ml： ...

进一步统计，近3个月内该股累计发生2笔大宗交易，合计成交金额为1.09亿元。 东诚药业12月9日大宗交易平台出现一笔成交，成交量600.00万股，成交金额8532.00万元，大宗交易成 交价为14.22元，相对今日收盘价折价3.00%。该笔交易的买方营业部为机构专用，卖方营业部为长江证 券股份有限公司上海徐汇区天钥桥路证券营业部。 证券时报·数据宝统计显示，东诚药业今日收盘价为14.66元，下跌0.95%，日换手率为0.78%，成交额为 8592.68万元，全天主力资金净流出465.30万元，近5日该股累计下跌2.14%，近5日资金合计净流出 2044.09万元。 （文章来源：证券时报网） 据天眼查APP显示，烟台东诚药业集团股份有限公司成立于1998年12月31日，注册资本82459.5705万人 民币。（数据宝） 12月9日东诚药业大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 溢价（%） | 业部 | | | 600.00 | ...

Core Viewpoint - Dongcheng Pharmaceutical (002675) has seen its stock price decline by 0.54% to 14.8 yuan, with a total market capitalization of 12.204 billion yuan. The company announced that its subsidiary, Nanjing Jiangyuan Andico, has had its product, Technetium-99m (99mTc) tilmanocept injection, included in the National Medical Insurance Directory, which is expected to aid in market promotion and future sales, although it will not significantly impact the company's financial performance until the directory takes effect on January 1, 2026 [1]. Group 1 - As of December 8, 2025, Dongcheng Pharmaceutical's stock closed at 14.8 yuan, down 0.54% from the previous trading day, with a total market value of 12.204 billion yuan [1]. - The stock opened at 15.08 yuan, reached a high of 15.25 yuan, and a low of 14.76 yuan, with a trading volume of 1.03 billion yuan and a turnover rate of 0.93% [1]. - The inclusion of the 99mTc tilmanocept injection in the National Medical Insurance Directory is expected to facilitate market promotion and future sales [1]. Group 2 - The product is indicated for diagnosing adults with suspected coronary artery disease through myocardial perfusion imaging [1]. - The announcement states that the inclusion in the insurance directory will not have a significant impact on the company's operating performance until it is implemented on January 1, 2026 [1].

Group 1 - The core announcement is that Yantai Dongcheng Pharmaceutical Group Co., Ltd.'s subsidiary, Yantai Lanacheng Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of the drug 177Lu-LNC1009 injection, which targets advanced malignant solid tumors [1][2] - The drug 177Lu-LNC1009 is a dual-target radioactive therapy aimed at FAP-positive and integrin αvβ3-positive patients, showing potential for improved tumor targeting and treatment efficacy [2][3] - The total research and development investment for 177Lu-LNC1009 has reached approximately 13.579 million yuan [2] Group 2 - The company announced that its full subsidiary, Nanjing Jiangyuan Andico Positron Research and Development Co., Ltd., has had its product, Technetium-99m (99mTc) Tetrofosmin injection, included in the National Medical Insurance Directory for 2025, which is expected to enhance market accessibility and promote sales [4] - The inclusion in the medical insurance directory will officially take effect on January 1, 2026, and is not expected to have a significant impact on the company's financial performance in the short term [4]

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., received approval from the National Medical Products Administration of China for the clinical trial of Lu-LNC1009 injection, which will commence shortly [1] Group 1: Product Development - The product Lu-LNC1009 injection is a dual-target radioactive internal therapy drug that targets fibroblast activation protein (FAP) and integrin αvβ3 [1] - It is intended for the treatment of patients with advanced malignant solid tumors that are positive for FAP and integrin αvβ3 [1] - Currently, there are no similar products available in the domestic or international markets, and there are no related sales data [1]